The benefit is questionable. The danger is real.

Quote




































Looks like dona may have just run the table on lecanemab. Efficacy vs lecanemab, dosing duration, cost on shorter dosing, and perhaps safety. 6 months head start to fade quickly?
 






anonymous said:
Looks like dona may have just run the table on lecanemab. Efficacy vs lecanemab, dosing duration, cost on shorter dosing, and perhaps safety. 6 months head start to fade quickly?
Click to expand...

Might not even get six months. Growing numbers are pushing to delay rollout while the (potentially very serious) safety issues are figured out.
 












Top Bottom
Back
Quote